CTOs on the Move

ZestDentalSolutions

www.zestdent.com

 
ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zestdent.com
  • 2875, Loker Avenue East
    Carlsbad, CA USA 92010
  • Phone: 800.262.2310

Executives

Name Title Contact Details

Similar Companies

Ionwerks

Ionwerks is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KCR

KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.

Purdue Pharma

Purdue Pharma is a research-based pharmaceutical company with its headquarters and manufacturing operations located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and ADHD. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma group of companies.

Diaceutics PLC

Diaceutics believe that every patient should get the treatment they deserve. We have worked on every Precision Medicine brought to market and we are trusted by the worlds leading pharmaceutical companies. Find out about DXRX - the Diagnostic Network f...

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).